Health Care [ 3/12 ] | Biotechnology [ 10/73 ]
NASDAQ | Common Stock
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.
In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs.
The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023.
The company was incorporated in 2013 and is based in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 25 | -0.15 Increased by +88.97% | -0.77 Increased by +80.61% |
| Aug 5, 25 | -0.49 Increased by +43.02% | -0.75 Increased by +35.00% |
| May 13, 25 | -0.60 Increased by +50.00% | -0.84 Increased by +28.57% |
| Feb 26, 25 | -0.81 Increased by +80.00% | -0.94 Increased by +14.22% |
| Nov 7, 24 | -1.36 Increased by +85.44% | -0.82 Decreased by -65.85% |
| Aug 7, 24 | -0.86 Increased by +98.48% | -0.95 Increased by +9.47% |
| May 9, 24 | -1.20 Increased by +73.63% | -1.17 Decreased by -2.56% |
| Feb 29, 24 | -4.05 Increased by +19.00% | -0.78 Decreased by -419.23% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -11.18 M Increased by +83.80% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -36.72 M Increased by +5.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -44.77 M Decreased by -2.09% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -56.30 M Increased by +10.90% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -69.03 M Decreased by -72.11% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -38.84 M Increased by +82.11% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -43.86 M Decreased by -138.07% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.04 M Increased by +520.24% | -63.18 M Decreased by -235.67% | Decreased by -6.06 K% Increased by +45.88% |